Piramal Pharma Limited (PPL) announced that Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India.
 
PPL holds a strategic minority stake in Yapan and markets its services through Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organization (CDMO) serving the global pharma and biopharma market.
 
With this expansion, Yapan has enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. The expansion includes three upstream suites (including Bio-Safety Level-2 containment), a downstream process development lab, an analytical development lab, and supporting infrastructure. The new labs will allow Yapan to optimize the utilization of the GMP facility to support manufacturing of clinical trial material for the clients. 
 
The new facility was inaugurated by Mr. K.T. Rama Rao, Minister for Municipal Administration & Urban Development, Industries & Commerce, and Information Technology of Telangana; Ms. Nandini Piramal, Chairperson, Piramal Pharma Ltd; Mr. Harinder S. Sikka, Group Director, Strategic Business, Piramal Enterprises Limited; and Atin Tomar & Nirav Desai, Founders of Yapan Bio. Mr. Jayesh Ranjan, IAS, Principal Secretary (IT, E&C), Government of Telangana, Mr. Shakthi Nagappan, Director (LS), Government of Telangana, and Mr. Pachipala Dora Swamy, Touchstone Property Developers Private Limited, were also present during the event.
 
Hon’ble Minister Mr. K.T. Rama Rao said, “It is heartening to see that Yapan Bio and Piramal Pharma have been continuously expanding from Genome Valley. This is testament to the strength of the biotechnology industry of Telangana. The state of Telangana has been working with the industry to see how to best match our policies and incentives to their constantly evolving needs. We will continue to be a partner for growth and ensure that companies like Yapan Bio continue to grow from the cluster.”
 
Ms. Nandini Piramal, Chairperson of Piramal Pharma Ltd. said, “This new facility, which is part of our 8 million USD expansion plan for Yapan Bio, represents the first major step in the Piramal/Yapan partnership since our initial investment back in December 2021. It’s evidence of our commitment to Yapan and the large molecule CDMO business, as well as our commitment to patients. With this investment, the Yapan team can conduct a larger number of projects than before, resulting in the development and delivery of more novel products for clinical evaluation and ultimately, better, and faster treatments for patients.”